Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma.

Cancer Med · 2023 · PMC10134287 · PMID 36726287

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

However, a numerical trend was observed for OS in favor of Isa‐Kd compared with Dara‐Rd after matching adjustment. 3.4.

also in 273 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.